Silk route to the acceptance and re-implementation of bacteriophage therapy.

Bacterial Infections/therapy; Consensus; Drug Resistance, Multiple, Bacterial; Ethics, Medical; Humans; Phage Therapy/adverse effects/ethics/methods; Practice Guidelines as Topic

Abstract :

[en] This multidisciplinary expert panel opinion on bacteriophage therapy has been written in the context of a society that is confronted with an ever-increasing number of antibiotic resistant bacteria. To avoid the return to a pre-antibiotic era, alternative treatments are urgently needed. The authors aim to contribute to the opinion formation of relevant stakeholders on how to potentially develop an infrastructure and legislation that paves the way for the acceptance and re-implementation of bacteriophage therapy.

Disciplines :

Microbiology

Author, co-author :

Alavidze, Z.

Betts, A.

Bardiau, Marjorie ; Université de Liège - ULiège > Bibliothèque des Sciences de la vie

Bretaudeau, L.

Caplin, J.

Chanishvili, N.

Coffey, A.

Cooper, I.

De Vos, D.

Doskar, J.

More authors (19 more)

Language :

English

Title :

Silk route to the acceptance and re-implementation of bacteriophage therapy.

Publication date :

2016

Journal title :

Biotechnology Journal

ISSN :

1860-6768

eISSN :

1860-7314

Publisher :

Wiley - VCH Verlag GmbH & Co. KGaA, Germany

Volume :

Issue :

Pages :

595-600

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 10 November 2020

Statistics

Number of views

88 (7 by ULiège)

Number of downloads

61 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., Knight, R., Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489, 220-230.
Mitchell, R. K., Agle, B. R., Wood, D. J., Toward a theory of stakeholder identification and salience: Defining the principle of who and what really counts. AMR 1997, 22, 853-886.
Pirnay, J. P., Blasdel, B. G., Bretaudeau, L., Buckling, A. et al., Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 2015, 32, 2173-2179.
Hall, J. P., Harrison, E., Brockhurst, M. A., Viral host-adaptation: Insights from evolution experiments with phages. Curr. Opin. Virol. 2013, 3, 572-577.
Friman, V. P., Soanes-Brown, D., Sierocinski, P., Molin, S. et al., Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. J. Evol. Biol. 2016, 29, 188-198.
Kirby, A. E., Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PloS One 2012, 7, e51017.
Mahony, J., McAuliffe, O., Ross, R. P., van Sinderen, D., Bacteriophages as biocontrol agents of food pathogens. Curr. Opin. Biotechnol. 2011, 22, 157-163.
Yosef, I., Manor, M., Kiro, R., Qimron, U., Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl. Acad. Sci. USA 2015, 112, 7267-7272.
Le, S., He, X., Tan, Y., Huang, G. et al., Mapping the tail fiber as the receptor binding protein responsible for differential host specificity of Pseudomonas aeruginosa bacteriophages PaP1 and JG004. PloS One 2013, 8, e68562.
Lu, T. K., Collins, J. J., Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. USA 2007, 104, 11197-11202.
Westwater, C., Kasman, L. M., Schofield, D. A., Werner, P. A. et al., Use of genetically engineered phage to deliver antimicrobial agents to bacteria: An alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 2003, 47, 1301-1307.
Lu, T. K., Collins, J. J., Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. USA 2009, 106, 4629-4634.
Merabishvili, M., De Vos, D., Verbeken, G., Kropinski, A. M. et al., Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. PloS One 2012, 7, e52709.
Verbeken, G., Pirnay, J. P., De Vos, D., Jennes, S. et al., Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch. Immunol. Ther. Exp. 2012, 60, 161-172.
van Zimmeren, E., Vanneste, S., Matthijs, G., Vanhaverbeke, W., Van Overwalle, G., Patent pools and clearinghouses in the life sciences. Trends Biotechnol. 2011, 29, 569-576.